Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.

Published in: Hematology (Amsterdam, Netherlands) (2023)

Our results showed that the combination of VEN + HMA appeared to be a highly effective and well-tolerated salvage therapy option for young patients with R/R AML, enabling more young patients to proceed to potentially curative allo-HSCT. However, additional, well-designed studies with larger numbers of patients are required to confirm the advantages of VEN + HMA in this population.

Keyphrases

acute myeloid leukemia
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
acute lymphoblastic leukemia
peritoneal dialysis
patient reported outcomes
stem cells
bone marrow